Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: A phase III, multicenter, randomized study

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 5, 2014, Pages 2993-3002

  Sheppard, John D ^a   Toyos, Melissa M ^b   Kempen, John H ^c   Kaur, Paramjit ^d   Foster, C Stephen ^e  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Toyos Clinic   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ALCON RESEARCH LTD   (United States)

^e MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Acute anterior uveitis; Corticosteroid; Difluprednate; Endogenous anterior uveitis; Intraocular pressure; Noninfectious uveitis; Prednisolone; Prednisolone acetate; Uveitis

Indexed keywords

DIFLUPREDNATE; PREDNISOLONE ACETATE;

ADOLESCENT; ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; BLURRED VISION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FEMALE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UVEITIS; VISUAL ACUITY; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT;

ACUTE ANTERIOR UVEITIS; CORTICOSTEROID; DIFLUPREDNATE; ENDOGENOUS ANTERIOR UVEITIS; INTRAOCULAR PRESSURE; NONINFECTIOUS UVEITIS; PREDNISOLONE; PREDNISOLONE ACETATE; UVEITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUPREDNISOLONE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PREDNISOLONE; UVEITIS, ANTERIOR; YOUNG ADULT;

EID: 84900029135     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12660     Document Type: Article

References (33)

1. American Optometric Association. Optometric Clinical Practice Guideline: Care of the Patient With Anterior Uveitis. St. Louis, MO: American Optometric Association; 1994. Reviewed 2004.
2. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218:223-236.
3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140: 509-516.
4. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in north-eastern Italy: analysis of 655 new cases. Acta Ophthalmol Scand. 2001;79: 64-68.
5. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol. 2007;18:476-480.
6. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ. 2000;320:555-558.
7. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111:2299-2306.
8. Lardenoye CW., van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113: 1446-1449.
9. Merck. The Merck manual for health care professionals: overview of uveitis. 2008. Available at: http://www. merckmanuals.com/professional/eye_disorders/uveitis_and_ related_disorders/overview_of_uveitis.html. Accessed March 17, 2014.
10. Sen HN, Drye LT, Goldstein DA, et al. Hypotony in patients with uveitis: the Multicenter Uveitis Steroid Treatment (MUST) Trial. Ocul Immunol Inflamm. 2012;20:104-112.
11. Pred Forte (prednisolone acetate ophthalmic suspension, USP), 1% [package insert]. Irvine, CA: Allergan, Inc.; 2004.
12. Vandenbroeck S, De Geest S, Dobbels F, Fieuws S, Stalmans I, Zeyen T. Prevalence and correlates of self-reported non-adherence with eye drop treatment: the Belgian Compliance Study in Ophthalmology (BCSO). J Glaucoma. 2011;20:414-421.
13. American Academy of Ophthalmology. Young ophthalmologists: 10 clinical pearls for treating uveitis. 2013. Available at: http://www.aao.org/yo/newsletter/200808/article05.cfm. Accessed March 17, 2014.
14. Tajika T, Waki M, Tsuzuki M, Kida T, Sakaki H. Pharmacoki-netic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011;27:29-34.
15. Bodor N, Harget AJ, Phillips EW. Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach. J Med Chem. 1983;26:318-328.
16. Donnenfeld ED, Holland EJ, Solomon KD, et al. A multicenter randomized controlled fellow eye trial of pulse-dosed diflu-prednate 0.05% versus prednisolone acetate 1% in cataract surgery. Am J Ophthalmol. 2011;152:609-617.
17. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:26-34.
18. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2008. Available at: http://www.wma.net/en/30publications/ 10policies/b3/. Accessed March 17, 2014.
19. Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475-483.
20. Biswas J, Ganeshbabu TM, Raghavendran SR, Raizada S, Mondkar SV, Madhavan HN. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis: a randomized triple masked study. Int Ophthalmol. 2004;25:147-153.
21. Udoetuk JD, Dai Y, Ying GS, et al. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology. 2012;119:1569-1574.
22. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
23. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008;4:453-461.
24. Durezol (difluprednate ophthalmic emulsion 0.05%) [package insert]. Fort Worth, TX: Alcon Research Ltd.; 2012.
25. Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;4:1119-1124.
26. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-334.
27. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9:361-375.
28. Cable MM. Intraocular pressure spikes in phacoemulsification patients using difluprednate ophthalmic emulsion 0.05% postoperatively twice daily and once daily. 2011. Available at: http://ascrs2011.abstractsnet.com/acover.wcs?entryid1/4000027. Accessed March 17, 2014.
29. Tran VT, Mermoud A, Herbort CP. Appraisal and management of ocular hypotony and glaucoma associated with uveitis. Int Ophthalmol Clin. 2000;40:175-203.
30. Meehan K, Vollmer L, Sowka J. Intraocular pressure elevation from topical difluprednate use. Optometry. 2010;81:658-662.
31. Birnbaum AD, Jiang Y, Tessler HH, Goldstein DA. Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate. Arch Ophthalmol. 2011;129:667-668.
32. Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;1535:932-938.
33. Kurz PA, Chheda LV, Kurz DE. Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. Ocul Immunol Inflamm. 2011;19:84-85.